ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities, alleging misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 29, 2024, and June 27, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Unicycive overstated its readiness to meet FDA requirements and the prospects of its oxylanthanum carbunate New Drug Application [5]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].